So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Viking Therapeutics is a clinical-stage biotech that's looking to compete with Lilly in weight loss treatment. Viking recently revealed plans to develop an obesity treatment that could be superior ...

About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...